We are excited to announce that entX Limited has been awarded a $2,915,000 grant from the Department of Industry, Science and Resources as part of the Cooperative Research Centres Projects (CRC-P) grant program, for Round 16!
This grant will support our “Mines to Medicines – Sovereign Nuclear Medicine Supply Chains from Waste” project within our Nuclear Medicine business, IsoMedica.
We are embarking on a groundbreaking initiative to establish a sovereign supply chain for lead-212 (Pb-212), a vital isotope used in Targeted Alpha Therapy (TAT) for advanced metastatic cancers, including prostate cancer and neuroendocrine tumours.
Well done to our amazing team at entX on making this happen and our partners at the University of South Australia, Tellus Holdings, iPHASE Technologies and AdvanCell Isotopes.
